A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects

Status:	Recruiting
Conditions:	Dermatology
Therapuetic Areas:	Dermatology / Plastic Surgery
Healthy:	No
Age Range:	18 - 65
Updated:	4/3/2019
Start Date:	November 26, 2018
End Date:	March 17, 2021
Contact:	Pfizer CT.gov Call Center
Email:	ClinicalTrials.gov_Inquiries@pfizer.com
Phone:	1-800-718-1021

A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06651600 WITH A PARTIALLY BLINDED EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF PF-06651600 AND PF-06700841 IN SUBJECTS WITH ACTIVE NON-SEGMENTAL VITILIGO

This is a Phase 2b, randomized, double blind, parallel group, multicenter study with an
extension period. The study will have a maximum duration of approximately 60 weeks. This
includes an up to 4 weeks Screening Period, a 24 week dose ranging period, an up to 24 week
extension period and a 8 week Follow up Period.

Inclusion Criteria:

- Male or female subjects between 18-65 years of age, inclusive, at time of informed
consent.

- Must have moderate to severe active non-segmental vitiligo.

Exclusion Criteria:

- History of human immunodeficiency virus (HIV) or positive HIV serology at screening,

- Infected with hepatitis B or hepatitis C viruses.

- Have evidence of active or latent or inadequately treated infection with Mycobacterium
tuberculosis (TB)

We found this trial at

sites

Vitiligo & Pigmentation Institute of Southern California

Los Angeles, California 90036

from

Los Angeles, CA